Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies

NCT04114136 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

72

Enrollment

OTHER

Sponsor class

Conditions

Melanoma
NSCLC
Hepatocellular Carcinoma
Urothelial Cancer
Gastric Adenocarcinoma
HNSCC
Esophageal Adenocarcinoma
Microsatellite Instability-High Solid Malignant Tumor

Interventions

DRUG: Nivolumab or Pembrolizumab (dependent upon approved indication)
DRUG: Metformin
DRUG: Rosiglitazone

Sponsor

Dan Zandberg